Fast and Sensitive Pharmacokinetic Assessment Using an Agilent LC/MS Triple Quadrupole System

Significance of the topic

Reliable and sensitive pharmacokinetic evaluation is crucial during early drug discovery to inform lead optimization and to reduce animal use. Simultaneous quantification of multiple compounds accelerates throughput and conserves biological resources.

Objectives and study overview

This work aimed to develop a generic, high-throughput LC/MS/MS protocol for simultaneous measurement of 26 antiepileptic drugs in plasma. Three analytes—gabapentin, tiagabine and lamotrigine—were selected for in vivo pharmacokinetic profiling in rats using a cassette dosing strategy.

Methodology

Samples were prepared by simple protein precipitation from 50 µL plasma. Chromatographic separation employed an Agilent ZORBAX Eclipse Plus Phenyl-Hexyl column (2.1×50 mm, 1.8 µm) with a 6-minute gradient using ammonium acetate/formic acid buffers in water and methanol. Mass spectrometric detection used dynamic multiple reaction monitoring (DMRM) on an Agilent 6495 Triple Quadrupole with iFunnel and ESI-AJS in both positive and negative modes. Calibration curves covered 0.3–20,000 nM with linear (1/y) regression, and LOQs ranged from 0.31–9.77 nM.

Used instrumentation

• Agilent 1290 Infinity II LC system with binary pump, multisampler (multiwash feature), and diode array detector
• Agilent ZORBAX Eclipse Plus Phenyl-Hexyl column (2.1×50 mm, 1.8 µm, 50 °C)
• Agilent 6495 Triple Quadrupole MS with ESI-AJS source and iFunnel technology

Main results and discussion

The method resolved all 26 drugs in under 6 minutes with baseline separation and sharp peaks. Validation for gabapentin, tiagabine and lamotrigine yielded accuracy within 90–110%, precision RSD <5% (LOQ RSD <10%), and correlation coefficients >0.99. The autosampler multiwash feature reduced carryover to below 0.1% for all three analytes. Rat pharmacokinetics showed low clearance and long half-lives for gabapentin and lamotrigine, and higher clearance for tiagabine, with measurable plasma levels up to 48 hours.

Benefits and practical applications of the method

The generic assay supports high-throughput screening of multiple drug candidates, lowering analysis time and sample volume requirements. Minimal carryover and wide dynamic range improve reliability. Cassette dosing with this approach streamlines early PK evaluation, enabling fewer animals and faster go/no-go decisions.

Future trends and potential applications

Expansion to metabolite profiling and broader therapeutic panels could further accelerate preclinical studies. Integration with high-resolution mass spectrometry, automated sample handling and AI-driven method optimization may enhance throughput and adaptability to complex matrices. Clinical therapeutic drug monitoring may also benefit from this rapid multi-analyte platform.

Conclusion

A robust, sensitive and high-throughput LC/MS/MS method was established for 26 antiepileptic drugs, with full validation for key analytes and successful application to rat PK studies. The workflow delivers rapid results with minimal consumables and supports efficient lead optimization workflows.

Reference

1. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239-1249.
2. Nagilla R, Kagan L, Kuo MS, Kirchner M, Yu LX. Cassette dosing for pharmacokinetic screening in drug discovery: comparison of clearance, volume of distribution, half-life, mean residence time, and oral bioavailability obtained by cassette and discrete dosing in rats. J Pharm Sci. 2011;100(9):3862-3874.
3. Korfmacher WA, Johnson TR. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun Mass Spectrom. 2001;15(5):335-340.